A summary of early access schemes in Europe and a look at how they can accelerate patient access. These are particularly important for patients with severe, life-threatening, or severely debilitating conditions to give access to medicines that do not yet have an MA and would otherwise be unavailable.

A brief explanation of commonly used buzzwords in Artificial Intelligence, and how using AI can help market access professionals in their day-to-day work.

The do's and don'ts of how to communicate the value of your health technology, to achieve a better chance of reimbursement.

In celebration of  MAP's 10-year anniversary, founder Christian Hill and Chief Executive Officer Dan Spacie reflect on MAP's journey so far and take a look at  future plans.

NICE's Early Value Assessment (EVA) initiative aims to provide quicker access for patients to medication and medical devices. This blog outlines the key points from a recent webinar.

The Evidence Base hosted a webinar on 21^st July entitled Accelerated regulatory approval in 2022 and beyond – managing uncertainty with the impact of Brexit and COVID.

The Market Access process in Ireland looks simple. However, in reality the timeline of the HTA process is usually unpredictable and there are significant delays in post-HTA recommendation due to limited government staff capacity and drug budget.

Today is the annual International Day of Immunology. That might once have been largely of interest to immunologists, but we are all immunologists now. The arrival of SARS-CoV-2 has changed the way the world looks at immunology.

Unlike other European healthcare systems, Switzerland does not have a free state-run healthcare system. Instead, health insurance is compulsory and is run primarily by the private sector.

The UK’s plastic packaging tax finally rolled into action on 1^st April 2022. Manufacturers and importers of plastic packaging containing less than 30% recycled plastic content will now be taxed at a rate of £200 per metric tonne.

Introduced in 2014, EAMS aims to give patients with life-threatening or seriously debilitating conditions access to medicines when there is a clear unmet need. The scheme is voluntary and does not replace the normal licensing procedures.